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Catheter ablation of atrial fibrillation is a modern therapeutic method that effectively
prevents arrhythmia recurrences. Because of the complexity nature of this procedure, it is
not surprising that the rate of complications is higher compared with other types of
catheter ablations. This review focuses on the most important complications, and
discusses their prevention, diagnosis and therapy.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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Over the past decade, catheter ablation has emerged as an
effective treatment option for treatment of patients withch Society of Cardiology.
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(B. Aldhoon).symptomatic paroxysmal or persistent atrial fibrillation
(AF). Because of the complex nature of the procedure, there
is an increased risk of various complications that can occur
during or after the procedure. Compared with other ablationPublished by Elsevier Urban & Partner Sp.z o.o. All rights reserved..
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tics that explain some specific complications. Multiple vas-
cular accesses, high doses of anticoagulation agents,
transseptal puncture and long ablation time are character-
istic attributes. In addition, the left atrial wall is thin struc-
ture that is surrounded by other structures such as
esophagus. This explains potential for damage of the left
trial wall or esophageal wall. Despite continuous efforts to
improve safety, the incidence of major complications, usually
defined as a complication that result in permanent injury or
death, requires intervention or prolong or requires hospitali-
zation [1], is still relatively high. Understanding the patho-
genesis and risks of the procedure, as well as operator’s
experience are factors that help to minimize complications.
This review describes known complications of catheter abla-
tion of AF and provides insights into the evolving strategies to
minimize these complications.2. Incidence of complications in AF ablation
The incidence of complications associated with selective
ablation for AF ranges in several registries between 3.9%
and 6% [2–4]. This variation in incidence of complications
reflects the learning curve period and different adopted
technology and strategies in different centers. Data from
recent worldwide survey reported an overall incidence of
complications of 4.5% with fatal outcome in 0.15% [3]. Data
from high-volume single centers reported similar incidence
of major complications (Table 1). The most recent data that
reflect real life scenario come from the European EORP Pilot
registry with overall complication rate of 7.7%, of which 1.7%
was major [5]. The most frequent are vascular complications
(pseudoaneurysms, arterio-venous fistulas, and hematomas),
cardioembolic events (stroke and transient ischemic attacks),
and pericardial perforation (effusion/tamponade). The latter,
together with rare atrio-esophageal fistula, is the major cause
of possible fatal outcome.Table 1 – Type and prevalence of complications related to AF a
Spragg et al. (n¼641) Dagres
Thromboembolic events (%) 1.1 0.4
Cardiac tamponade (%) 1.2 1.3
Vascular complications (%) 1.7 1.3
Pulmonary vein occlusion (%) 0.1 0.1
Atrio-esophageal fistula (%) None 0.2
Heart block (%) 0.1 None
Acute lung injury (%) 0.1 None
Mitral valve injury (%) 0.1 None
Endocarditis (%) None 0.2
Deep vein thrombosis (%) None 0.1
Transient phrenic nerve injury (%) None None
Aspiration (%) None 0.2
Death of unclear cause (%) None 0.2
Overall rate of complications (%) 5 3.93. Thromboembolic complications
Thromboembolism is one of the most serious complications
of AF ablation. The incidence of periprocedural thromboem-
bolic events varies from 1% to 7%, depending on the ablation
strategy and anticoagulation regimen used in this period [3,6].
In one study, a high incidence of silent cerebral thromboem-
bolism following AF ablation has also been reported, however
its clinical impact is still not clear [7].
It is important to emphasize that each patient with AF has
a baseline risk for a thromboembolic event that can be
estimated by indices such as the CHADSVASc score [8].
Catheter ablation could further temporarily increase the risk
of thromboembolic events. A number of risk factors for the
development of thromboembolic complications have been
proposed. These include persistent activation of the coagula-
tion cascade due to intravascular placement of catheters [9]
and endothelial disruption resulting from ablation [10], car-
dioversion during AF ablation [7], impairment of normal left
atrial (LA) contraction or ‘‘atrial stunning’’ [11] and reduction
in the LA transport function [12], ablation of persistent AF
[13], and finally anticoagulation swing between warfarin
through low-molecular-weight heparin (LMWH) to intrave-
nous heparin and back to oral anticoagulation [14].
Thromboembolic events can occur during ablation proce-
dure or within a period up to 2 weeks after ablation. The
clinical manifestation varies according to location of the
involved arterial bed. The most feared is intracranial embo-
lism leading to stroke. Less common is coronary artery and/or
peripheral embolization. Cerebral embolization is usually
treated conservatively with heparin, whereas, in peripheral
embolization surgical embolectomy is also recommended.
Anticoagulation therapy during pre-, peri- and post-
ablation period is the cornerstone of prevention strategy for
thromboembolic events. Trans-esophageal echocardiography
(TEE) is recommended in intermediate to high risk patient
prior to procedure to exclude preformed thrombus in the LA.
However, we learned from previous practice of using intra-
cardiac echocardiography (ICE) that introducing needle orblation in selected single high-volume centers.
et al. (n¼1000) Baman et al. (n¼1642) Hoyt et al. (n¼1190)
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Fig. 1 – Lasso catheter introduced into the left atrium (LA)
shown by ICE. At the end of the catheter is seen fluttering
thrombus (arrow).
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 4 1 4 – e 4 2 0e416sheath into LA may quickly trigger a new thrombus forma-
tion. Because of this experience, we adopted a strategy of
administering intravenous heparin at the beginning of the
ablation procedure—well before the first transseptal punc-
ture. Additionally, intraprocedural TEE or ICE can be helpful
in stratifying high-risk patients with smoke-like echogenicity
in the LA. In these patients, more aggressive anticoagulation
regimen should be considered to prevent LA thrombus
formation [15]. ICE may also help in an early detection of
thrombus in LA during the procedure (Fig. 1).
Until recently, warfarin was usually stopped 3 days prior to
the procedure and ‘‘bridged’’ with LMWH. However, several
reports on periprocedural therapeutic anticoagulation with
warfarin showed a reduced risk of periprocedural stroke
without increased bleeding complications [16,17]. This has
resulted in a new trend towards performing ablation without
interruption of warfarin therapy. In the event of major
bleeding an activated factor VII can be infused to rapidly
reverse the effects of warfarin. Accordingly, we have modified
our strategy of anticoagulation therapy and perform ablation
procedures on uninterrupted warfarin therapy with INR in
the range of 2–2.5.
Recently, new anticoagulant agents, including thrombin
inhibitor and factor Xa inhibitor, have been introduced into
clinical practice. However, experience with catheter ablation
on this anticoagulation regimen is still very limited. In a
recent published study, Lakkireddy et al. found a higher
incidence of bleeding and pericardial effusions in patients
treated with dabigatran and no difference in the rate of
thromboembolism compared with warfarin [18].4. Air embolism
Other less frequent reason for embolic events is air embolism
that can occur mainly during introduction or flushing trans-
septal sheaths. The preferential localization for air emboli is
right coronary artery territory due to the most superior
position of the arterial ostium in the supine patient. Clinicalpresentation includes transient acute inferior ischemia and/or
heart block. Symptoms usually resolute within few minutes
and rarely is needed cardiopulmonary support. Prevention
measures include repeated and continuous flushing of sheaths
and careful removal of all air bubbles from sheaths.5. Cardiac tamponade
Cardiac tamponade is the other important complication that
may result in fatal outcome. Based on analysis of data from
registries, it is the most frequent cause of peri-procedural
death occurring in association with AF ablation [6]. Although
cardiac tamponade can occur in any ablation procedure, its
incidence is somewhat higher with AF ablation (0.8–2.9%)
[2,4,19]. This can be attributed to the complexity of the
procedure, including the common need for two or more
transseptal punctures, frequent manipulation with catheters,
extensive ablation, and high level of systemic anticoagulation.
Cardiac perforation leading to cardiac tamponade can
occur: (1) during transseptal puncture (puncture of the right
atrial posterior wall before entering the LA or puncture the
roof, appendage, or lateral LA wall), (2) during catheter
manipulation (tear of the LA appendage or roof of the LA),
or (3) during delivery of radiofrequency energy (overheating
with development of steam pop, leading to myocardial
rupture). In swine model, Eick et al. found a significant
association between sudden change in impedance and the
risk of developing tamponade [20].
It should be noted that delayed cardiac tamponade, defined
as cardiac tamponade occurring one hour or more following
an AF ablation procedure, has also been reported [3]. Cardiac
tamponade can also occur during cryoballoon ablation pro-
cedures with an overall incidence of cardiac tamponade up to
1.6% [21].
Clinically, cardiac tamponade presents either as an abrupt
dramatic fall in blood pressure, or more insidiously, as a
gradual decrease in blood pressure. Development of intrapro-
cedural hypotension in any patient should be assumed to be
due to tamponade until it is ruled out. A decreased excursion
of the left heart border on fluoroscopy in the left anterior
oblique projection is an early sign of cardiac tamponade.
Diagnosis can be immediately confirmed with transthoratic
echocardiography or ICE if used as part of the ablation
procedure.
Once the diagnosis of cardiac tamponade confirmed,
immediate percutaneous subxiphoid pericardiocentesis with
placement of intra-pericardial pig-tail catheter and reversal
of anticoagulation with protamine should be performed.
After pericardial drainage, the patient need to be monitored
with the drain left in place usually for 24 h. In most cases, the
bleeding stops spontaneously, but in some cases cardiac
surgery is required, especially in the presence of a tear. It is
important to be aware of the possibility of delayed tampo-
nade and include this entity in differential diagnosis of
hypotension hours or days after the procedure.
Minor pericardial effusion without acute hemodynamic
impact may be a result of an inflammatory reaction due to
applied radiofrequency current with reported overall inci-
dence of 0.8% [4].
Fig. 3 – Transeptal puncture performed under ICE control.
Image shows the needle engaging the fossa ovalis. LA; left
atrium.
Fig. 2 – Pericardial effusion shown by ICE (arrow), which
arose during isolation of right pulmonary veins. LV; left
ventricle.
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 4 1 4 – e 4 2 0 e417ICE has been reported to allow earlier detection of a
pericardial effusion [22] (Fig. 2). From our experience we
found that the routine use of ICE may also reduce the risk
of cardiac tamponade [13]. ICE enables to perform transseptal
puncture under visual control of the tip of the needle
engaging the fossa ovalis (Fig. 3). LA mapping and ostia of
pulmonary veins tagging could also be easily performed.
Finally, ICE can be used to monitor the course of radio-
frequency applications, the position and the contact of
ablation catheter with the tissue and switch off current
application whenever sudden tissue whitening or bursts of
microbubbles are observed.6. Vascular complications
Vascular complications are the most frequent complications
of catheter ablation for AF. These include hematoma,retroperitoneal hematoma, pseudoaneurysm, arteriovenous
fistula and hemothorax due to subclavian or internal jugular
venous access. Higher incidence of vascular complication
likely reflects the number and the size of venous sheaths
deployed in the setting of intense anticoagulation prior to
and following the ablation procedures. An adequate hemos-
tasis following sheath removal is essential. Anticoagulation
regimen in the peri-ablation period seems to be an important
factor in the occurrence of vascular complications. In a study
by Prudente et al., an aggressive anticoagulation protocol of
enoxaparin (1 mg/kg10 doses) resulted in higher incidence
of vascular complications compared to low doses (0.5 mg/
kg6 doses) [5.7% vs. 1.6%, Po0.03 ] [23]. Many other studies
have already shown that performing AF ablation on unin-
terrupted anticoagulation with warfarin compared with
heparin ‘‘bridging’’’’ has emerged with favorable safety results
[14,24–27].
Recently, other risk factors such as venous access gaining
by less experience follows [28], and lower body weight [13]
have been shown to increase vascular complication inci-
dence. The diagnosis and the management of vascular
complications are based on general approaches of adequate
hemostasis. Most of vascular complications are managed
conservatively; however some vascular complications require
surgical intervention.7. Atrio-esophageal fistula
Atrio-esophageal fistula is the most serious potential com-
plication. Although its occurrence is rare (0.1–0.25%) [3], its
mortality rate is higher than 80% and survivors of this
complication are often left with disability from cerebrovas-
cular events. Cadaveric studies have elucidated the relation-
ship between the posterior wall of the LA and esophagus. The
esophagus frequently courses within 5 mm of the atrial
endocardium at some point in its path. The variable amount
of fibro-fatty tissue interposed between the atrium and
esophagus can contain vagal nerves and esophageal arteries
exposing these structures to potential injury from ablation
[29]. The thickness of the fat pad separating the left atrium
and esophagus is variable and dependent on age, gender,
body weight and left atrial size [29,30]. Application of radio-
frequency lesions to the posterior wall is the most important
factor responsible for esophageal injury [31]. Ablation of
persistent AF as compared with paroxysmal AF is also a risk
factor for esophageal injury probably due to more extensive
ablation in persistent AF [32]. Gillinov et al. observed that
patients with lower body mass index are at a higher risk of
esophageal injury [33].
Clinical manifestation of atrio-esophageal fistula occurs
usually 2–4 weeks after the ablation procedure. The most
common symptoms comprise dysphagia, odynophagia, sep-
tic fever, gastrointestinal bleeding and recurrent neurological
events due to a massive air embolism. In case of suspicion on
atrio-esophageal fistula, urgent cardiac CT or MR scan is
recommended. Avoiding endoscopy examination is equally
important, since insufflation of the esophagus with air may
result in a large air embolus producing stroke or death. Once
the fistula is confirmed, urgent surgery is needed.
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 4 1 4 – e 4 2 0e418Because atrio-esophageal fistula is very serious complication,
it is important to make every effort to prevent it. Strategies
proposed to prevent esophageal injury during AF ablation
include reduced power titration while ablating the posterior
left atrium wall, limiting radiofrequency delivery time, using
conscious sedation rather than general anesthesia for better
pain perception, and monitoring intraprocedural esophageal
position in relation to the posterior left atrium wall [34–37].
In this respect, ICE is very useful in real-time visualization of
the esophagus. Others use real time temperature monitoring
within the esophagus during the procedure [38]. This is believed
to minimize excessive temperature rise in the esophagus and
decrease risk of development of the fistula. However, there is no
clear proof that this strategy avoids risk of atrio-esophageal
fistula. Whether routinely prescription of proton pump inhibi-
tors or H2 blockers reduce the risk of atrio-esophageal fistula is
still not clear.8. Pulmonary vein stenosis
Pulmonary vein (PV) stenosis was more frequent (up to 40%)
when ablation targeted focal triggers within the PVs [39].
Saad et al. in their early series of catheter ablation between
1998 and 2002 reported an overall incidence of PV stenosis of
15.6% [40]. Subsequent use of ICE to monitor catheter tip
position and tissue overheating resulted in abolition of the
risk [13]. The current strategy of ablation at the PV ostia
significantly decreased the incidence of PV stenosis
(0.4%–3.4%) [3,4]. The true incidence of PV stenosis is likely
underestimated as patient imaging is not routinely per-
formed in most electrophysiology laboratories. Although the
precise pathophysiological mechanisms are still uncertain, a
progressive vascular reaction including architectural remo-
deling, intimal proliferation and fibrosis, as well as thrombus
formation have been suggested [41,42].
Therefore, energy delivery distally within the PVs should be
avoided. Because PVs anatomy is very variable, CT or MR
imaging can help to clarify the anatomy of PVs. At our
centre we found ICE very helpful to visualize the ostia of
PVs and prevent ablation inside PVs.
Clinical signs of significant PV stenosis are not specific and
highly variable, and can range from asymptomatic in mild or
moderate to severe presentation. They may include cough,
dyspnea, hemoptysis, or recurrent pneumonia [40,43]. Symp-
toms usually develop several weeks to months after the
procedure. Diagnosis can be confirmed by CT or MRI scans.
Ventilation–perfusion scanning or transesophageal echocar-
diography with Doppler can also be used. The preferred
therapy for severe (470%) symptomatic PV stenosis is PV
balloon angioplasty or stenting [40,44,45]. However, resteno-
sis can develop despite stent placement and it is estimated to
be 44% to 70% [45–47].9. Phrenic nerve injury
Phrenic nerve paresis, likely from direct thermal injury, has
been described after RF ablation, cryoablation, ultrasound,
and laser ablation. The right phrenic nerve can be affectedduring ablation near the right superior PV or within the
superior vena cava, whereas, left phrenic nerve rarely
affected during ablation within the LA appendage [24,48].
The use of balloon technologies carries substantially higher
risk of this complication, since the balloon has to be pressed
inside the ostium and may prolapse deeper into the right
superior PV and cause the damage.
Symptoms are usually less pronounced (dyspnea, hiccups,
cough, pain, pleural effusion, or atelectasis) and in most
cases, phrenic nerve fiction recovers after several (typically
within 6–12) months. Diagnosis is confirmed on fluoroscopy
as unilateral diaphragmatic paralysis.
Strategies to prevent phrenic nerve injury include high
output pacing at vulnerable sites and avoiding ablation at
sites that stimulate the phrenic nerve.10. Injury to the vagus nerve
Injury to the vagal esophageal plexus can occur during RF
delivery to the posterior wall of the LA. This can lead to
pyloric spasm, gastric hypomotility, and a markedly pro-
longed gastric emptying time [49]. The common symptoms
are abdominal bloating and discomfort occurring hours to
days after the procedure [50,51]. Spontaneous recovery typi-
cally occurs but may require up to 12 months. Prevention
involves the same strategy as prevention of esophageal
injury.11. Other complications
Other less frequent complications can also occur. These
include atrioventricular block, sepsis, pericarditis, mitral
valve trauma and circular catheter entrapment and acute
coronary artery occlusion of the left circumflex coronary
artery.12. Experience of IKEM
Recently, we have published data on analysis of complica-
tions from our centre [13]. The study included consecutive
1192 AF ablation procedures in 959 patients. All procedures
were ICE-guided and performed by open-irrigated tip catheter
after switching from warfarin to heparin. The power mode
was used with a preset power up to 25–30W and down-
regulation when the tip temperature of 40–42 1C was
achieved. Constant irrigation flow of 15 ml/min (30 ml/min
inside the coronary sinus) was used. Forty major complica-
tions (3.3%) during the procedure or within the 3 month
follow-up were observed. No death or atrio-esophageal fistula
occurred. Three patients (0.25%) had cardiac tamponade/
hemopericardium and five patients (0.42%) had cerebrovas-
cular embolic event. Vascular injury was the most frequent
(2.3%) complication including 2 hemothorax, 2 retroperito-
neal bleeding, 1 subclavian vein bleeding, 7 femoral arterio-
venous fistulas, 4 femoral pseudoaneurysm and 12 groin
bleeding. There were also 1 pericarditis, 1 atriovenricular
block and 1 transient phrenic nerve paresis. Low body weight
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 4 1 4 – e 4 2 0 e419was the only significant risk factor with 0.8% increase of
complication rate per 10 kg of body weight decrease (P¼0.013).
A trend for increase in complication rate was also observed for
advanced age, female gender, and complex procedure i.e. that
with more than simple PV isolation.13. Conclusions
Catheter ablation is an effective treatment option for AF.
Although there is higher risk of major complications with this
procedure, considerable progress in prevention of these
events reduced the risk of their incidence. Physicians per-
forming these procedures must be vigilant for complications
and skilled in early treatment to increase the safety of AF
ablation procedure. Equally important is the fact that many of
complications may appear later after ablation, and therefore,
every cardiologist should be aware and learn about their
presentations and diagnosis.Funding
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